Incyte Corp
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.15%.
Did INCY Beat Earnings? Q2 2025 Results
Incyte delivered a convincingly strong second quarter, posting non-GAAP diluted EPS of $1.57 against a consensus estimate of $1.47, a beat of 6.48%, while total revenues of $1.22 billion cleared the $1.15 billion estimate by 5.81% and grew 16.5% year over year. The results were powered by broad commercial momentum: Jakafi contributed $763.79 million in net product revenues, up 8% year over year, while Opzelura surged 35% to $164.50 million on robust U.S. atopic dermatitis and vitiligo demand, and newly launched Niktimvo added $36.15 million in just its second full quarter on the market. A landmark settlement with Novartis, which secured a 50% reduction in ongoing Jakafi royalty rates beginning January 2025, provided a meaningful structural tailwind to margins going forward. Incyte raised its full-year Jakafi revenue guidance to $3.00 billion to $3.05 billion and lifted Other Oncology guidance to $500 million to $520 million, reflecting continued Niktimvo uptake and accelerating Zynyz demand following its FDA approval in squamous cell anal carcinoma.
- Jakafi 8% paid demand growth across all indications
- Opzelura 35% revenue growth driven by increased U.S. patient demand and refills in AD and vitiligo plus ex-U.S. launches in Italy and Spain
- Strong Niktimvo commercial launch uptake generating $36 million in its second full quarter
- Zynyz revenue growth driven by new SCAC approval
- Novartis royalty dispute settlement reducing Jakafi royalty rate by 50% effective January 1, 2025, resulting in $242.2 million net benefit
- Total royalty revenues grew 10% driven by Jakavi royalty growth
“As I begin my tenure as CEO, I look forward to leading Incyte through its next phase of growth and value creation for patients, partners and shareholders. Our second quarter results reflect strong growth for Jakafi® (ruxolitinib), Opzelura® (ruxolitinib) cream and Niktimvo™ (axatilimab), positioning us well to deliver on our 2025 objectives.”
Incyte CEO, on the earnings call
Forward Guidance & Outlook
Incyte raised full-year 2025 Jakafi net product revenue guidance to $3,000–$3,050 million (from $2,950–$3,000 million). Opzelura guidance remains unchanged at $630–$670 million. Other oncology net product revenue guidance raised to $500–$520 million (from $415–$455 million), reflecting Niktimvo launch strength, higher Zynyz demand, and positive FX impact. GAAP cost of product revenues guided at 8.0%–9.0% of net product revenues (from 8.5%–9.0%). GAAP R&D expenses increased to $1,965–$1,995 million (from $1,930–$1,960 million) reflecting new collaborations with Genesis and Biotheryx. Non-GAAP R&D expenses raised to $1,815–$1,840 million (from $1,780–$1,805 million). GAAP SG&A guidance unchanged at $1,280–$1,310 million. Key upcoming catalysts include Phase 3 tafasitamab data in first-line DLBCL (H2 2025), Phase 1 INCA033989 data in MF (H2 2025), KRASG12D and TGFβR2×PD-1 proof-of-concept data (H2 2025), and Opzelura pediatric AD PDUFA date of September 19, 2025.
INCY YoY Financials
INCY Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.